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Abstract
Following the onset of an ischemic brain injury, the excitatory neurotransmitter glutamate is released. The excitotoxic
effects of glutamate are a major contributor to the pathogenesis of a stroke. The aim of this study was to examine if
overexpression of a glutamate transporter (GLT-1) reduces ischemic brain injury in a rat model of stroke. We generated an
adeno-associated viral (AAV) vector expressing the rat GLT-1 cDNA (AAV-GLT1). Functional expression of AAV-GLT1 was
confirmed by increased glutamate clearance rate in non-stroke rat brain as measured by in vivo amperometry. AAV-GLT1
was injected into future cortical region of infarction 3 weeks prior to 60 min middle cerebral artery occlusion (MCAo). Tissue
damage was assessed at one and two days after MCAo using TUNEL and TTC staining, respectively. Behavioral testing was
performed at 2, 8 and 14 days post-stroke. Animals receiving AAV-GLT1, compared to AAV-GFP, showed significant
decreases in the duration and magnitude of extracellular glutamate, measured by microdialysis, during the 60 minute
MCAo. A significant reduction in brain infarction and DNA fragmentation was observed in the region of AAV-GLT1 injection.
Animals that received AAV-GLT1 showed significant improvement in behavioral recovery following stroke compared to the
AAV-GFP group. We demonstrate that focal overexpression of the glutamate transporter, GLT-1, significantly reduces
ischemia-induced glutamate overflow, decreases cell death and improves behavioral recovery. These data further support
the role of glutamate in the pathogenesis of ischemic damage in brain and demonstrate that targeted gene delivery to
decrease the ischemia-induced glutamate overflow reduces the cellular and behavioral deficits caused by stroke.
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Introduction
An ischemic stroke begins with obstruction of an arterial vessel
in the brain, progresses through a cascade of cellular and
molecular events, and ultimately leads to cell death. The initial
depletion of oxygen leads to a loss of cellular ATP and
dysregulation of ion homeostasis at the membrane [1]. The
altered ion homeostasis activates voltage-dependent calcium
channels and the depolarization of the neuronal membrane can
cause massive release of neurotransmitters such as glutamate. For
glutamatergic neurons, ischemia causes the release of glutamate
into the synaptic cleft and extracellular space. The excess
glutamate in the extracellular space causes extended activation
of ionotropic glutamate receptors (iGluRs). The resulting over-
stimulation of iGluRs activates intracellular signaling cascades
producing excitotoxicity and cell death [2]. The inhibition of
glutamate-induced excitotoxicity has been a therapeutic target for
the treatment of stroke for many years [3]. For example, acute
administration of NMDAR or AMPAR antagonists reduces
ischemic damage in rodent models of stroke [4,5]. Our lab has
also previously reported that blocking glutamate release or
glutamate-mediated post-synaptic excitability reduces neural
degeneration in stroke rats [6,7]. Taken together, these data
support that regulation of glutamate overflow during the ischemic
phase can alter outcomes in stroke animals, however, clinical
trials based on iGluR antagonists have failed with adverse CNS
effects and they possibly impede endogenous neurorepair
mechanisms [8].
The release of glutamate occurs within minutes of ischemic
onset and therapeutic drugs targeted at blocking excitotoxicity
must be administered rapidly or they lose their protective effect.
An alternative approach is to augment glutamate clearance from
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the extracellular space to prevent excitotoxic iGluR stimulation.
To date, there are five subtypes of the sodium-dependent
excitatory amino acid transporters (EAAT1-5) that differ in their
regional and cellular expression and ability to transport glutamate
[9]. Transient middle cerebral artery occlusion (MCAo) decreases
GLT-1 (EAAT2), a predominantly glia-expressed EAAT [10,11].
Furthermore, decreasing GLT1 mRNA using anti-sense knock-
down exacerbated neuronal death caused by transient MCAo
[12]. Certain small molecules such as beta-lactams have been
shown to increase the expression of the glutamate transporter in
the brain [13]. For example, Chu et al. demonstrated that
intraperitoneal administration of ceftriaxone (CTX) for five
consecutive days prior to stroke reduced infarction volume and
increased behavioral recovery [14,15]. To further explore this
treatment strategy of stroke by increasing glutamate clearance, we
generated an adeno-associated viral vector expressing the rat
GLT-1 cDNA (AAV-GLT1). Our data show that intracortical
delivery of AAV-GLT1 reduced ischemic damage and the
magnitude and duration of ischemia-induced glutamate overflow
caused by MCAo.
Materials and Methods
Animals
Adult male Fischer 344 rats (Harlan Laboratories Inc., IN) and
Sprague-Dawley rats (Charles River Laboratory, NC) were used
for amperometry and for MCAo studies, respectively and
maintained under a 12-hour light–dark cycle. Housing and
experimental procedures followed the guidelines of the ‘‘Principles
of Laboratory Care’’ (NIH publication No. 86-23, 1996) and
experimental procedures were approved by the NIDA Animal
Care and Use Committee (Animal Study Protocol#08-CNRB-73)
and the U. Kentucky Institutional Animal Care and Use
Committee (Animal Study Protocol#880M2005).
Construction, Packaging, Purification, and Titering of AAV
Vectors
The rat cDNA for GLT-1 was first PCR amplified from pc-
GLT-1 [16] (from Dr. Mike Robinson at U. Pennsylvania). The
amplified PCR product contained BamHI (59 end) and XbaI (39
end) restriction enzyme sites used to insert the PCR product into
pCR8/GW/TOPO (Invitrogen, CA) as an intermediate. The
BamHI/Xba1 fragment replaced GFP in the BamHI/XbaI
digestion of pssAAV-GFP [17] to create pssAAV-GLT1. Viral
stocks of AAV-GLT1 serotype 1 were prepared using the triple-
transfection method [17,18,19].
In vitro characterization
HEK293 cells (American Type Culture Collection,Manassas
VA) were transfected with AAV vector packaging plasmids
containing GFP or GLT-1 cDNAs using Lipofectamine 2000
(Invitrogen). Western blot analysis was performed as previously
described [20] using a mouse monoclonal anti-GLT1 antibody
(from Dr. Jeffrey Rothstein, Johns Hopkins University) [21,22].
Experiments were conducted twice with three wells of 24 well plate
per group.
Intracerebral AAV injections
For in vivo characterization by amperometry in control rats,
animals were anesthetized with isoflurane. AAV-GLT1 or AAV-
GFP/RFP (3 ul) was stereotaxically injection into the striatum
(AP: +1.0, ML: 2.5, DV: 24.5 mm).
For MCAo experiments: Animals were anesthetized with chloral
hydrate (0.4 g/kg, i.p.). AAV-GFP or AAV-GLT1 (2 ul per site;
titer ,1013 viral genomes/ml) was given intracerebrally into three
cortical sites in the distribution of the right MCA [20].
Quantification of extracellular glutamate by
amperometry
Three weeks after viral infusion, rats were anesthetized with
urethane (1.25 g/kg, i.p.). Ceramic-based microelectrode arrays
(MEAs) consisting of four platinum recording sites (156333 mm)
specific for glutamate were used for recordings [23]. Glutamate
(1 mM, 25–350 nL) was locally applied through a glass micropi-
pette. Glutamate clearance rate was examined at 0.1 mm lateral to
the infusion site (AP: +1.0, ML: 2.6 mm, DV: 24.5, mm).
Quantification of glutamate release during MCAo using
microdialysis and HPLC
The probe was stereotaxically placed in the parietal cerebral
cortex (24.0 mm posterior, 4.5 mm lateral to the bregma,
23.0 mm below brain surface). Artificial cerebrospinal fluid
(aCSF) was perfused through the probe at a rate of 261026 L/
min. Samples were collected at 20 min intervals. The concentra-
tion of glutamate in the dialysis samples was determined using
HPLC-based methods [24].
Middle cerebral artery occlusion (MCAo)
Three weeks after the AAV injections, animals were anesthe-
tized with chloral hydrate (0.4 g/kg, i.p.). The right MCA was
transiently ligated with 10-O suture for 60-minute [25]. Core body
temperature was maintained at 37uC with a heating pad during
surgery. After surgery, the animals were kept in a temperature-
controlled incubator to maintained body temperature at 37uC.
Triphenyltetrazolium chloride (TTC) staining
Animals were sacrificed 2 days after MCAo. The brain slices
(2 mm) were incubated in 20 g/L TTC [7].
Behavioral recovery
At 2, 8 and 14 days after stroke, the elevated body swing test for
body asymmetry and Bederson’s test for neurological deficits were
performed as previously described [20,26,27].
Histological analysis
Rats were decapitated 1 day after MCAo or 3 weeks after AAV-
GFP injection for TUNEL labeling as previously described [7].
Histological images taken from 0.05 mm slices were acquired
using Nikon Super Coolscan table scanner and pixel density of
TUNEL-positive nuclei per measured area of cortex was
quantified and averaged from three sections corresponding to
regions of TTC slices 3, 4 and 5. The TUNEL pixels density was
measured using NIS Elements 2.3 software.
Statistical analysis
Student’s t-test, (two-tailed) was used for statistical analysis
between two groups. For 2 factors (i.e. virus and time or virus and
tissue slice number) a 2-way ANOVA with Bonferonni post-hoc
analysis was used. Data are presented as mean 6 S.E.M.
Results
AAV-GLT1 characterization and distribution of viral gene
expression in vivo
The rat cDNA for the glutamate transporter 1 was successfully
subcloned into an AAV vector to generate pssAAV-GLT1 as
determined by DNA sequencing (data not shown). Expression of
AAV-GLT1 Reduces Ischemic Brain Injury
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the rat GLT1 protein was confirmed by western blot analysis of
protein extracts prepared from HEK293 cells transfected with the
pAAV-GLT1 packing plasmid into HEK293 cells (Figure 1A).
Primary cortical neurons transduced with AAV-GLT1 virus
exhibited increased GLT1 immunoreactivity that was localized
throughout the cell (Figure S1). Biochemical function of GLT-1
protein was verified in vivo using glutamate specific electrodes and
amperometry in adult rat brain three weeks after AAV-GLT1
injections (Figure 1B and 1C). The glutamate clearance (Tc) was
significantly faster in striata injected with AAV-GLT1 (n = 3 rats)
compared to those injected with AAV-GFP (n = 3 rats),
(F(1,16) = 31.97, p,0.0001, n = 3; Figure 1C.
The distribution of viral transduction by AAV serotype 1 was
examined at three weeks after intracortical AAV-GFP injection
(n = 3 rats). There is a widespread distribution of GFP fluorescence
in cortical region which colocalizes to both neurons (NeuN
immunopositive) and astrocytes (GFAP immunopositive; Figure 2).
AAV-GLT1 reduces infarction and improves behavioral
recovery
Cerebral infarction was examined by TTC at 2 days after MCAo.
Pretreatment with AAV-GLT1 (n = 7 rats) significantly reduced
infarction compared to AAV-GFP injections (n = 8 rats; Figure 3A,
p,0.01, Student’s t-test and Figure 3C, p,0.05, 2-way ANOVA).
Post-hoc analysis indicates that the significant reduction of
infarction by AAV-GLT1 occurred on brain sections containing
the cortical region corresponding to the site of intracortical
injections of AAV-GLT1 (Figure 3B, p,0.05, Bonferroni post-test).
Functional recovery was examined at 2, 8 and 14 days after the
MCAo in 16 rats. AAV-GLT1 (n = 8 rats) injection significantly
reduced body asymmetry in an elevated body swing test (Fig. 4A,
p,0.0001, 2-way ANOVA ) and Bederson’s neurological
abnormality scores (Fig. 4B, p,0.001, 2-way ANOVA). Prior to
MCAo surgery, animals showed no significant difference in
baseline locomotor activity for any parameters (i.e. horizontal
activity, vertical activity, total distance or stereotypy (data not
shown). No significant difference in locomotor activity was
observed at 24 hours post-stroke between AAV-GLT1 and
AAV-GFP treated animals (data not shown).
Physiological parameters were measured before and 30 minute
after MCAo. We found no significant difference in blood pH,
blood pressure, temperature, hematocrit% or blood gas levels
between AAV-GFP and AAV-GLT1 treated animals (Table 1).
These data suggest the protective effects of AAV-GLT1 were not
due to systemic changes.
AAV-GLT1 decreases ischemia-induced glutamate
overflow in lesioned cortex
To determine whether the overexpression of GLT1 reduced
glutamate efflux caused by ischemia, we performed in vivo
microdialysis to sample extracellular fluid in the cortical region
corresponding to the AAV-GLT1 or AAV-GFP injection prior,
during and after the 60 minute MCAo in 8 rats. An increase in
extracellular glutamate was detected at 20 minutes after MCAo
initiation for both AAV-GFP (n = 4 rats) and AAV-GLT1 (n = 4
rats) treated animals (Figure 5). Glutamate remained elevated until
20 minutes after the 60 minute MCA occlusion in the AAV-GFP
treated animals. A significant reduction in ischemia-induced
glutamate overflow was found in animals receiving AAV-GLT1
(p =,0.0001, 2-way ANOVA). Glutamate levels returned to
baseline by 40 minutes after MCAo initiation in the AAV-GLT1-
treated animals (Figure 5).
MCAo-related TUNEL was reduced by AAV-GLT1
TUNEL was examined in the lesioned cortical region at 24 hours
after the onset of ischemia in 14 rats. Animals that received
pretreatment with AAV-GLT1 (n = 7 rats) showed a significant
(48%) reduction in TUNEL staining compared to the AAV-GFP
(n = 7 rats) treated animals (Figure 6, p,0.05, Student’s t-test).
These data further support that AAV-GLT1 conferred a protective
effect against MCAo-induced ischemia.
Figure 1. Characterization of AAV-GLT1 in vitro and in vivo. (A)
Western blot analysis for GLT-1 protein in HEK293 cells that were
transfected with the AAV-GLT1 packaging plasmid for 24 hours. GLT-1
appears as two prominent bands 150 kD and 60 kD [21,22]. (B)
Representative graphs showing time course of glutamate signals
(amplitudes in 170–185 uM glutamate range) and the faster glutamate
clearance rate in the striatum of animals injected with AAV-GLT1
compared to AAV-GFP. (C) Glutamate clearance (Tc) in the striatal
hemisphere treated with AAV-GLT1 was significantly increased com-
pared to the AAV-GFP -treated hemisphere. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0022135.g001
AAV-GLT1 Reduces Ischemic Brain Injury
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Figure 2. Transduction of rat cortex by three site injection of AAV-GFP serotype 1. (A) Schematic representation of rat skull with injection
sites (black dots). (B) Dashed line points to brain section cut in a sagittal plane showing 3 injections sites by GFP fluorescence (green;scale = 0.5 mm).
(C) Coronal section of injection site showing expression of GFP from a dsAAV1eGFP injection. Coronal sections immunostained for neuronal marker,
NeuN (red; D–F) or the astrocytic marker, GFAP (red;G–I) show that GFP (green) colocalizes to both neurons and astrocytes in the cortex. Arrowheads
illustrate example of NeuN (D,E) or GFAP (G,H) double-labeled cells. Scale bar = 100 um.
doi:10.1371/journal.pone.0022135.g002
Figure 3. AAV-GLT1 significantly reduces infarction size in region of viral injection. Local administration of AAV-GLT1 reduced brain
infarction. (A) AAV-GLT1 significantly reduced the maximal infarct area compared to AAV-GFP treated animals (p,0.01, Student’s t-test). (B) Analysis
of infarction based on 2 mm brain section showed a significant reduction in brain infarction in animals treated with AAV-GLT1 (p,0.01, Two-way
ANOVA). Significant differences in the infarction area per slice were observed in slices 3 through 5 (arrows) which contain the viral injection sites
(*p,0.05). (C) Representative 2 mm brain sections stained with TTC. Rats received 3 cortical injections of AAV-GLT1 or AAV-GFP into the right
hemisphere.
doi:10.1371/journal.pone.0022135.g003
AAV-GLT1 Reduces Ischemic Brain Injury
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Discussion
In the current study, we successfully generated and character-
ized an AAV vector to express rat GLT-1 cDNA (AAV-GLT1).
Using AAV-GLT1, we demonstrated that over-expression of
GLT1 in rat parietotemporal cortex 3 weeks prior to MCAo
reduced infarction caused by MCAo, improved neurological
deficits, decreased the magnitude and duration of ischemia-
induced glutamate overflow and attenuated ischemia-related
TUNEL staining. Collectively, our data indicated that increasing
the capacity to clear extracellular glutamate via gene transfer
provides beneficial outcomes against ischemia-induced glutamate
release and associated excitotoxicity.
The overflow of glutamate following ischemia has been known
for over 25 years [28]. Excess extracellular glutamate causes
increased activation of ionotropic GluRs such as NMDA and, to a
lesser extent, AMPA. The increased influx of calcium due to the
activation of post-synaptic iGluRs initiates a range of neurotoxic
cascades [2]. Studies have shown that acute administration of the
NMDAR or AMPAR antagonists reduce ischemic damage in
rodent models of stroke [4,5]. Our lab also reported that
pharmacological agents that block glutamate-mediated post-
synaptic excitability or glutamate release can reduce neural
degeneration in stroke rats [6,7]. Our current study confirms the
significant contribution of ischemia-induced glutamate overflow to
the pathogenesis of stroke. Additionally, our study extends the
pharmacological manipulation of GLT1 levels [13,14,15] to
genetic manipulation of GLT1 as a gene therapy approach to
reducing ischemia-induced excitotoxicity. Here, we used an AAV
vector to deliver the rat GLT1 cDNA to rat cortex prior to
ischemia and showed that the duration and magnitude of
ischemia-induced glutamate overflow was significantly reduced.
We observed a significant reduction in the amount of infarcted
tissue and ischemia-induced TUNEL staining in the region of
tissue transduced with AAV-GLT1. These histological findings
support that augmenting GLT1 expression is protective against the
ischemic damage. There was also a progressive improvement in
the recovery of neurological deficits (Bederson’s score) and body
asymmetry in animals that received AAV-GLT1 but not the
control virus AAV-GFP. Collectively, the behavioral data also
suggest that overexpression of AAV-GLT1 at the time of ischemia
can reduce the ischemia-induced glutamate overflow and confer
protection against excitotoxicity.
Endogenous GLT1 is primarily localized to perisynaptic
membranes of astrocytes [29]. By using an AAV serotype 1 which
transduces both neurons and glia in rat cortex [17], we are able to
target GLT1 on both neuronal and astrocytic membranes. In
primary cortical neurons, we observed GLT1 expression distributed
Figure 4. AAV-GLT1 promotes behavioral recovery after
cerebral ischemia. Behavioral tests were carried out at 2, 8 and 14
days after the MCAo and analyzed with 2-way ANOVA. AAV-GLT1
injection significantly reduced body asymmetry in an elevated body
swing test (A) and neurological abnormality scores in Bederson’s test
(B). *p,0.05, **p,0.01, ***p,0.001; Bonferroni test.
doi:10.1371/journal.pone.0022135.g004
Table 1. GLT1 over-expression did not alter physiological
parameters 30 min after MCAo.
GFP GLT1 * p
pH 7.4460.01 7.4260.03 0.57
PaCO2 mmHg 37.862.3 41.863.4 0.36
PaO2 mmHg 98.365.3 93.366.9 0.59
MBP mmHg 99.564.2 96.069.6 0.75
Hematocrit % 37.861.5 33.062.4 0.15
doi:10.1371/journal.pone.0022135.t001
Figure 5. Pre-treatment with AAV-GLT1 reduces glutamate
overflow in stroke rats. Microdialysis was performed in the lesioned
cortex. In animals receiving AAV-GFP, MCAo caused an increase in
extracellular glutamate. In animals receiving AAV-GLT1, MCAo -induced
glutamate overflow was significantly reduced (p,0.01, Two-way, AAV-
GLT1 vs AAV-GFP post-MCAO;*p,0.05, **p,0.01, ***p,0.001; Bonfer-
roni test.
doi:10.1371/journal.pone.0022135.g005
AAV-GLT1 Reduces Ischemic Brain Injury
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throughout GLT1-immunoreactive cells. Using our 3 site injection
paradigm of AAV1-GFP, we observed widespread distribution
pattern of GFP that colocalized to both neurons (NeuN-positive)
and astrocytes (GFAP-positive cells). These data support that the
overexpression of GLT1 is widely distributed with respect to the
cellular elements that would transport elevated glutamate following
ischemia.
We, and others, previously reported that pretreatment with
GluR antagonists reduces ischemic brain damages in experimental
animals [30]. On the other hand, we also found excitatory amino
acids have trophic response to developing neurons [31,32].
Furthermore, systemic administration of the N-methyl-D-aspartate
(NMDA) receptor blocker MK-801 suppressed the elevated
neurogenesis in hippocampus after MCAo in rats [33]. These
data support two opposite reactions of GluR antagonists in stroke.
Systemic application of GluR antagonists reduces neurodegener-
ation in the ischemic region, but attenuates neuroregeneration in
non-injured regions. These conflicting responses may result in the
failure in clinical trials of using GluR antagonists in stroke patients
[34]. A proper approach would be reducing glutamate concen-
trations or responses locally in the lesioned area while preserving
the endogenous glutamate function in areas for neurogenesis, such
as subventricular zone [35]. Such an approach was shown in this
study where overexpression of GLT1 in the ischemic cortex
reduces the size of lesion and improves the behavioral recovery up
to two weeks after stroke.
The experimental approach used in this study evaluated
glutamate clearance following ischemia-induced overflow where
the glutamate transporter had been genetically manipulated to be
overexpressed in the region of ischemia. The findings of reduced
glutamate overflow and reduced ischemic damage further support
strategies aimed at reducing the duration and magnitude of
extracellular glutamate caused by an ischemic event. Although
clinical trials targeted at systemic glutamate suppression failed, the
current study suggests that focal glutamate clearance may be
beneficial. For example, people at risk for transient ischemic
attacks, previous surgery, heart attack or other non-preventable
risk factors for stroke may benefit from elevated GLT-1 levels
Figure 6. Pre-treatment with AAV-GLT1 reduces TUNEL staining following MCAo. TUNEL was examined at 24 hours after MCAo in the
region of infarction near site of viral transduction. (A) Schematic of coronal secion near bregma indicating cortical region (box) of representative
images in C–F. (B) AAV-GLT1 significantly reduced TUNEL staining in ischemic cortex compared to AAV-GFP (p,0.05, Student’s t-test). Representative
TUNEL from AAV-GFP (C) and AAV-GLT1(D). Cresyl violet staining in on adjacent brain sections from AAV-GFP (E) and AAV-GLT1(F) treated animals.
Scale bar = 0.2 mm.
doi:10.1371/journal.pone.0022135.g006
AAV-GLT1 Reduces Ischemic Brain Injury
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caused by focal pharmacological [13,14,15] or genetic manipula-
tion as less invasive and selective delivery of genes to the brain
emerges.
Summary
In conclusion, we used a viral vector-mediated gene delivery
approach to increase the expression of GLT-1 locally and reduce
the damage caused by brain ischemia in a rodent model of stroke.
Our data support approaches to selectively upregulate endogenous
GLT-1 in the cortex for the protection against stroke [13,14,15].
Further development of selective gene delivery may make the use
of GLT1 a more viable gene therapy approach for neurodegen-
eration caused by glutamate excitotoxicity.
Supporting Information
Figure S1 GLT-1 immunostaining (red) of rat primary
cortical neurons nine days after transduction with
control virus (AAV-GFP) or AAV-GLT1. Nuclei stained with
DAPI (blue). Primary cortical neurons from E15 Sprague-Dawley
rat embryos [19] were transduced with AAV-GFP or AAV-GLT1
on DIV6. Cells were fixed on DIV15 and were immunostained
using rabbit polyclonal anti-GLT1 antibody using methods
previously described [19]. Experiments were conducted on two
independent primary culture preparations with 6 wells of 96 well
plate per group.
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